Abstract

Exogenous CD1d-binding glycolipid (α-Galactosylceramide, α-GC) stimulates TCR signaling and activation of type-1 natural killer–like T (NKT) cells. Activated NKT cells play a central role in the regulation of adaptive and protective immune responses against pathogens and tumors. In the present study, we tested the effect of Bacillus anthracis lethal toxin (LT) on NKT cells both in vivo and in vitro. LT is a binary toxin known to suppress host immune responses during anthrax disease and intoxicates cells by protective antigen (PA)-mediated intracellular delivery of lethal factor (LF), a potent metalloprotease. We observed that NKT cells expressed anthrax toxin receptors (CMG-2 and TEM-8) and bound more PA than other immune cell types. A sub-lethal dose of LT administered in vivo in C57BL/6 mice decreased expression of the activation receptor NKG2D by NKT cells but not by NK cells. The in vivo administration of LT led to decreased TCR-induced cytokine secretion but did not affect TCR expression. Further analysis revealed LT-dependent inhibition of TCR-stimulated MAP kinase signaling in NKT cells attributable to LT cleavage of the MAP kinase kinase MEK-2. We propose that Bacillus anthracis–derived LT causes a novel form of functional anergy in NKT cells and therefore has potential for contributing to immune evasion by the pathogen.

Highlights

  • CD1d-restricted Type I natural killer–like T (NKT) cells are central regulators of adaptive immune responses [1]

  • We have observed that anthrax toxins adversely affect a type of cell in the immune system known as a natural killer–like T (NKT) cell

  • We report that anthrax toxins effectively shut down NKT cells, preventing them from functioning normally

Read more

Summary

Introduction

CD1d-restricted Type I NKT cells are central regulators of adaptive immune responses [1]. NKT cells can be activated with exogenous CD1d-binding glycolipid antigen (Ag) to boost humoral immunity and prime CTL responses specific for co-administered Ag [2,3,4]. The mechanisms by which NKT cells enhance antibody (Ab) responses are unclear but involve cognate and non-cognate interactions between NKT cells and B cells [5,6,7]. NKT cells can drive DC maturation and induction of tumor-specific CTL [8,9], a mechanism likely important for NKT-enhanced tumor rejection [4,10]. There is evidence for increased priming of Th responses as a result of NKT activation suggesting an important contribution to the initiation of adaptive immunity [4]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call